Biosynex SA (FR:ALBIO) has released an update.
Biosynex’s subsidiary, Chembio Diagnostics, has received a $1.5 million grant from the Bill & Melinda Gates Foundation to develop a rapid diagnostic test for congenital syphilis, a growing global health concern. The test aims to offer a quick, accurate, and affordable solution, particularly in low and middle-income regions, enhancing early diagnosis and treatment of syphilis in newborns and pregnant individuals.
For further insights into FR:ALBIO stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
